Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls Sells 54,702 Shares

Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls sold 54,702 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. This represents a 3.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Savara Trading Down 6.2 %

Shares of NASDAQ:SVRA opened at $3.02 on Thursday. Savara Inc has a 52 week low of $2.82 and a 52 week high of $5.70. The company’s 50 day moving average is $3.49 and its two-hundred day moving average is $4.00. The company has a market cap of $518.29 million, a PE ratio of -7.02 and a beta of 0.92. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). Equities analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Hedge funds and other institutional investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. boosted its holdings in Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after buying an additional 3,443,541 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Savara by 90.5% in the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock valued at $18,377,000 after buying an additional 2,165,701 shares during the last quarter. First Light Asset Management LLC acquired a new stake in Savara during the 2nd quarter worth $8,069,000. Finally, Wellington Management Group LLP lifted its position in Savara by 22.9% in the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after acquiring an additional 1,608,522 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Tuesday, October 1st. Finally, HC Wainwright decreased their target price on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.